Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy

Fig. 6

MET-CAR-T killing activity on tumor organoids derived from primary human gastric cancer cells overexpressing the MET receptor. (A) Representative pictures of organoids derived from GTR-468 primary gastric carcinoma cells grown in a three-dimensional matrix in the presence of #948 MET-CAR-T for 3 or 5 days. Cancer cells were stained with NucBlue (Blue signal), and T cells were stained with PHK26 (Red signal) Magnification, 20x; scale bars, 75 μm. (B) Tumor organoid elimination mediated by MET-CAR-T quantified by measuring NucBlue fluorescence loss after 5 days of co-culture. (C) Representative maximum intensity projections of confocal microscopy images of GTR-468-derived organoids (blue) treated with MET-CAR-T or not-transduced T cells (red; E:T ratio, 2:1). Confocal microscopy images taken after 48 hours of co-culture. Magnification, 20x; scale bars, 75 μm. (D) Quantification of MET-CAR-T infiltration into GTR-468-derived organoids by the analysis of red fluorescence PKH26 area (px2). CTRL: Untreated organoids; NTD: Organoids treated with not-transduced T cells; #948: Organoids treated with MET-CAR-T. Bars: SEM. Statistical significance was calculated by Two-way Anova, corrected Bonferroni. Stars indicated P values: * P ≤ 0.05; ** P ≤ 0.01

Back to article page